CD4 and neoplasm: This immunogenic response to the tumor was further enhanced by eribulin, but not by paclitaxel, as observed by the increase in activated CD4+ T-cells in both the spleen and the tumor draining lymph nodes of eribulin-treated tumored animals (Figure 7B,C).